Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Emanuela Sant'Antonio

Epidemiology and Clinical Relevance of Mutations in Postpolycythemia Vera and Postessential Thrombocythemia Myelofibrosis: A Study on 359 Patients of the AGIMM Group

American Journal of Hematology

Hematology

2016

English

Related publications

Updates in the Management of Polycythemia Vera and Essential Thrombocythemia

Therapeutic Advances in Hematology

Hematology

2019

English

Recent Advances in Understanding Myelofibrosis and Essential Thrombocythemia

English

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Journal of Clinical Oncology

English

SF3B1 Mutations in Primary Myelofibrosis: Clinical, Histopathology and Genetic Correlates Among 155 Patients

English

A Higher JAK2 V617f-Mutated Clone Is Observed in Platelets Than in Granulocytes From Essential Thrombocythemia Patients, but Not in Patients With Polycythemia Vera and Primary Myelofibrosis

English

Phenotypic Variations and New Mutations in JAK2 V617F–negative Polycythemia Vera, Erythrocytosis, and Idiopathic Myelofibrosis

Experimental Hematology

English

Driver Mutations and Prognosis in Primary Myelofibrosis: Mayo-Careggi MPN Alliance Study of 1,095 Patients

American Journal of Hematology

Hematology

2017

English

A Phase 2 Study of Simtuzumab in Patients With Primary, Post-Polycythaemia Vera or Post-Essential Thrombocythaemia Myelofibrosis

British Journal of Haematology

Hematology

2017

English

ASXL1 Mutations in Chinese Patients With Essential Thrombocythemia

Experimental and Therapeutic Medicine

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Emanuela Sant'Antonio

Epidemiology and Clinical Relevance of Mutations in Postpolycythemia Vera and Postessential Thrombocythemia Myelofibrosis: A Study on 359 Patients of the AGIMM Group

Related publications

Updates in the Management of Polycythemia Vera and Essential Thrombocythemia

Recent Advances in Understanding Myelofibrosis and Essential Thrombocythemia

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

SF3B1 Mutations in Primary Myelofibrosis: Clinical, Histopathology and Genetic Correlates Among 155 Patients

A Higher JAK2 V617f-Mutated Clone Is Observed in Platelets Than in Granulocytes From Essential Thrombocythemia Patients, but Not in Patients With Polycythemia Vera and Primary Myelofibrosis

Phenotypic Variations and New Mutations in JAK2 V617F–negative Polycythemia Vera, Erythrocytosis, and Idiopathic Myelofibrosis

Driver Mutations and Prognosis in Primary Myelofibrosis: Mayo-Careggi MPN Alliance Study of 1,095 Patients

A Phase 2 Study of Simtuzumab in Patients With Primary, Post-Polycythaemia Vera or Post-Essential Thrombocythaemia Myelofibrosis

ASXL1 Mutations in Chinese Patients With Essential Thrombocythemia